Indivior PLC (NASDAQ:INDV) Receives Consensus Rating of “Moderate Buy” from Brokerages

Indivior PLC (NASDAQ:INDV) has received an average recommendation of “Moderate Buy” from the seven analysts that are covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $43.6667.

Several equities analysts have weighed in on INDV shares. Zacks Research downgraded Indivior from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 29th. Barclays assumed coverage on shares of Indivior in a research report on Thursday, June 18th. They set an “overweight” rating and a $46.00 price target on the stock. Finally, Weiss Ratings raised shares of Indivior from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, July 24th.

Insider Buying and Selling

In other Indivior news, insider Christian Heidbreder sold 18,586 shares of the stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $41.14, for a total transaction of $764,628.04. Following the sale, the insider directly owned 209,337 shares in the company, valued at $8,612,124.18. This represents a 8.15% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Ryan Preblick sold 36,000 shares of the firm’s stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $37.70, for a total transaction of $1,357,200.00. Following the completion of the transaction, the chief financial officer directly owned 284,751 shares of the company’s stock, valued at $10,735,112.70. This represents a 11.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.74% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Salomon & Ludwin LLC purchased a new position in Indivior in the fourth quarter valued at $30,000. Harbor Capital Advisors Inc. increased its holdings in Indivior by 309.9% during the 4th quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock worth $37,000 after purchasing an additional 781 shares during the period. Quarry LP acquired a new stake in Indivior in the 3rd quarter valued at about $26,000. Caitong International Asset Management Co. Ltd raised its position in Indivior by 72.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock valued at $39,000 after purchasing an additional 460 shares in the last quarter. Finally, Rockefeller Capital Management L.P. boosted its stake in shares of Indivior by 512.4% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,286 shares of the company’s stock valued at $46,000 after buying an additional 1,076 shares during the period. 60.33% of the stock is currently owned by hedge funds and other institutional investors.

Indivior Trading Down 0.5%

Shares of NASDAQ INDV opened at $40.01 on Friday. Indivior has a twelve month low of $19.31 and a twelve month high of $42.81. The stock has a fifty day simple moving average of $39.18 and a 200-day simple moving average of $35.48. The stock has a market capitalization of $4.88 billion, a PE ratio of 20.52 and a beta of 0.86.

Indivior (NASDAQ:INDV) last posted its earnings results on Tuesday, March 31st. The company reported $0.96 earnings per share (EPS) for the quarter. Indivior had a negative return on equity of 219.26% and a net margin of 19.44%.The firm had revenue of $317.00 million for the quarter. On average, equities analysts predict that Indivior will post 4.05 earnings per share for the current year.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.